The Insulin Peptide Family

Apr 11, 2013

Insulin is only one member of a family of peptide hormones and growth factors that comprises 10 members in humans: insulin, insulin-like growth factors I and II and seven peptides related to relaxin. Pierre de Meyts at FeF Chemicals A/S looks into how invertebrates also have many insulin-like peptides, and how they play an important role in metabolism, growth, reproduction and longevity. [prettyfilelink src=”http://ipimediaworld.com/wp-content/uploads/2013/04/1-The-Insulin-Peptide-Family.pdf” type=”pdf”]1 The Insulin Peptide Family[/prettyfilelink] ...

Read More

Optimised Connectivity is Fundamental to Integrity & Safety of Hygienic Processing

Apr 11, 2013

Every product for consumption, ingestion, injection, or cosmetic use must be safe for use and be in perfect condition when used. Micro- organisms, toxic substances and any other contaminants that could impair quality or introduce risk are not permitted. Marc Klingler at Bürkert discusses these dangers and how a hygienic processing production plant has to ensure that all necessary measures are taken to be certain that public safety and wellbeing are preserved. [prettyfilelink src=”http://ipimediaworld.com/wp-content/uploads/2013/04/1-Optimised-Connectivity-is-Fundamental-to-Integrity-Safety-of-Hygienic-Processing.pdf” type=”pdf”]Optimised Connectivity is Fundamental to Integrity & Safety of Hygienic Processing[/prettyfilelink] ...

Read More

Patient Recruitment: The Most Recognised Silent Driver of Clinical Development Costs.

Apr 11, 2013

Patient recruitment challenges the drug development process for a number of reasons. Elio Evangelista at Cutting Edge Information discusses why the increased demand for clinical trial patients, combined with the relatively flat growth in clinical investigators and study sites, places the pharmaceutical industry in a predicament. [prettyfilelink src=”http://ipimediaworld.com/wp-content/uploads/2013/04/Patient-Recruitment-The-Most-Recognized-Silent-Driver-of-Clinical-Development-Costs.pdf” type=”pdf”]Patient Recruitment The Most Recognized Silent Driver of Clinical Development Costs[/prettyfilelink] ...

Read More

Personalised Medicine Inventions – Is Patent Protection Possible?

Apr 11, 2013

Personalised Medicine Inventions – Is Patent Protection Possible? A recent decision from the US Supreme Court now questions whether patent protection for personalised medicine and diagnostic inventions will be available in the US. Jodie Albutt at Dehns looks into what this decision means for the protection of innovation in this field, and contrasts this to the situation in Europe, which may be more positive. [prettyfilelink src=”http://ipimediaworld.com/wp-content/uploads/2013/04/Personalised-Medicine-Inventions-Is-Patent-Protection-Possible1.pdf” type=”pdf”]Personalised Medicine Inventions Is Patent Protection Possible?[/prettyfilelink] ...

Read More

Biobank Management Systems

Apr 11, 2013

Biobanks are increasingly playing an important role in biotechnology, pharmaceutical and medical research. John Boother at Autoscribe Ltd looks into why the ability to manage an ever-increasing number of bio-samples, and to comply with the regulatory requirements, is a high priority for all organisations working in this area. [prettyfilelink src=”http://ipimediaworld.com/wp-content/uploads/2013/04/Biobank-Management-Systems.pdf” type=”pdf”]Biobank Management Systems[/prettyfilelink] ...

Read More